skip to main content

What are the demonstrated medical benefits and anti-ageing effects of

Guideline-aligned answer with reasoning, red flags and references. Clinically reviewed by Dr Kola Tytler MBBS CertHE MBA MSt MRCGP.

Posted: 23 August 2026Updated: 23 August 2026 Guideline-Aligned (High Confidence) Clinically Reviewed

Bottom line: In humans, non-invasive red/NIR photobiomodulation (PBM; low-level laser/LED therapy) has its strongest demonstrated benefits as supportive treatment for treatment-related mucosal/skin injury, selected wound-healing and postoperative indications, some pain/rehabilitation indications, and ophthalmic applications; evidence for “anti-ageing” is preliminary, condition-specific, and does not establish reversal of systemic biological ageing.

What has been demonstrated clinically: In oncology supportive care, randomized and pragmatic human studies report reductions in oral mucositis severity and pain, preservation of taste, and less radiotherapy-associated dermatitis with red/NIR PBM.

  • In 46 patients receiving head-and-neck radiotherapy, 808/905-nm PBM reduced grade 2–3 acute radiation dermatitis by 49% versus sham/standard skin care at treatment completion.
  • In a 72-patient radiotherapy cohort receiving 1,312 exposures of 650-nm LED PBM, no device-related adverse events were reported, grade-3 mucositis or dermatitis was uncommon (≤5%), and more than 70% of pre-existing lesions improved or stabilised.
  • In children with chemotherapy-induced oral mucositis, a four-day 980-nm PBM regimen reduced pain by day 10 and mucositis severity by day 14, with no adverse events reported.
  • In double-blind chemotherapy prophylaxis trials, intraoral red PBM, with or without extraoral NIR PBM, left 73–86% of participants free of oral mucositis after one to two weeks versus universal mucositis in controls, and improved oral-health quality-of-life measures.
  • Daily 660-nm PBM during haematopoietic-cell transplantation reduced hypogeusia, ageusia and parageusia and prevented lingual-papillae atrophy versus sham treatment.

For tissue repair and postoperative recovery, human trials report improved wound closure in diabetic foot ulcers, lower pain and oedema after dental/maxillofacial surgery, and faster recovery after selected cosmetic and orthopaedic procedures.

  • In a double-blind RCT of 30 people with grade-II diabetic foot ulcers, 904-nm PBM accelerated wound closure and was associated with lower VEGF and higher nitric-oxide concentrations.
  • In a split-mouth trial after third-molar surgery, 810-nm PBM reduced pain and oedema at 24 and 48 hours versus sham irradiation.
  • In 145 post-blepharoplasty participants, 830-nm LED PBM reduced swelling, pain and anxiety compared with conventional care, without reported side effects.
  • After carpal-tunnel release, an 808-nm PBM course improved symptom scores, morning pain, pinch strength and sensory discrimination over up to six months.
  • After arthroscopic rotator-cuff surgery, self-administered 808-nm PBM improved pain, function, quality of life, and the likelihood of achieving patient-important symptom thresholds at three to six months.

For pain and musculoskeletal disorders, results are mixed rather than uniformly positive.

  • Triple-blind placebo-controlled fibromyalgia trials reported reduced tender points and improved clinical-impact measures without adverse events, and another whole-body PBM trial reported durable pain reduction and better self-efficacy through six months.
  • A pain-point-targeted 780-nm PBM protocol improved temporomandibular-disorder pain more than fixed anatomical-point treatment in an RCT of 54 women.
  • Conversely, adding PBM to exercise did not improve outcomes over exercise alone in a 127-participant knee-osteoarthritis RCT, and a Cochrane review evaluated adjunctive therapies alongside land-based exercise because exercise remains the core recommended intervention for hip or knee osteoarthritis.
  • PBM did not improve repeated-sprint performance in elite basketball players, and PBM with or without stretching did not attenuate delayed-onset muscle soreness or improve recovery in untrained adults.

Anti-ageing-relevant human effects: The best-supported interpretation is improvement in selected age-associated functional deficits rather than proven whole-body rejuvenation.

  • In older adults with mild cognitive impairment, 60 days of transcranial NIR PBM improved Montreal Cognitive Assessment scores and increased serum BDNF, with benefit persisting at three months and no adverse change in NSE or S100B markers.
  • Home transcranial PBM in mild cognitive impairment due to Alzheimer disease improved cognitive scores over 12 weeks without reported adverse events, while smaller studies reported gains in functional autonomy in Alzheimer disease/mild cognitive impairment and in working memory in subjective cognitive decline.
  • Small Parkinson disease studies suggest feasibility and possible stabilisation or improvement in motor, gait, balance and cognitive measures with long-term home PBM, but sample sizes were small and sham-controlled between-group significance was limited.
  • In early/intermediate dry age-related macular degeneration, PBM improved visual acuity and reduced drusen burden in sham-controlled trials; one multicentre study reported a 20.3% versus 8.9% rate of at least five-letter acuity improvement, with mild transient ocular irritation in 20% of treated participants.
  • In non-exudative AMD, multiwavelength 590/660/850-nm PBM improved best-corrected visual acuity and was associated with less new geographic atrophy over 13 months, without phototoxicity or inflammation.
  • In paediatric myopia trials, repeated 650-nm red-light treatment reduced axial elongation and refractive progression, including in premyopia and high myopia, with OCT-based assessments reporting no retinal structural damage during 12-month follow-up.
  • A small facial-rejuvenation RCT in women aged 45–60 used sham-controlled 660-nm LED PBM with objective wrinkle and skin-imaging assessments, but the supplied evidence does not establish durable clinical reversal of cutaneous ageing or a systemic anti-ageing effect.

Skin appearance versus medical photodynamic therapy: The red-light photodynamic-therapy evidence in actinic keratosis should not be conflated with PBM because it uses topical 5-aminolaevulinic acid to generate intracellular protoporphyrin IX and phototoxic reactive oxygen species that destroy target cells.

Nevertheless, this medically supervised 630–635-nm red-light treatment demonstrates that visible-red illumination can have clinically meaningful skin outcomes in a different, photosensitiser-dependent treatment paradigm.

For example, field-directed ALA red-light photodynamic therapy achieved 90.9% complete patient clearance and 94.3% lesion clearance versus 21.9% and 32.9% with placebo at 12 weeks in one actinic-keratosis trial, with skin-quality measures continuing to improve through 12 months.

Narrow-spectrum red-light PDT also produced more transient treatment-site pain and erythema than broad-spectrum illumination, illustrating that safety and tolerability depend on the treatment protocol and are not interchangeable across light-based interventions.

Safety evidence: Across controlled human PBM studies, adverse effects were usually absent, mild or transient, but safety conclusions are indication- and device-specific rather than universal.

  • Reported tolerability signals include transient mild ocular irritation in AMD treatment, brief weakness or fine-motor slowing in a Parkinson disease crossover study, and minimal self-limiting adverse events in a chemotherapy-induced peripheral-neuropathy trial.
  • Trials in mucositis, radiodermatitis, postoperative recovery, fibromyalgia, multiple sclerosis and myopia commonly reported no serious or no treatment-related adverse events under their specified protocols.
  • Oncological use requires protocol-specific scrutiny because PBM effects can be parameter dependent and concerns remain about unintended stimulation of tumour biology, despite supportive-care studies reporting favourable short-term safety.
  • Consumer-device claims should be interpreted cautiously because wavelength, irradiance, fluence, beam geometry, target depth, pulse pattern and cumulative dose vary substantially, and incomplete reporting plus small, heterogeneous trials limit reproducibility and meta-analysis.

Clinical interpretation: PBM is most defensible as a protocol-specific adjunct where a relevant human trial base exists, particularly for oral mucositis/radiation injury, selected postoperative or wound-healing indications, and certain retinal conditions.

Claims that red or NIR devices broadly “reverse ageing,” reliably enhance athletic performance, or treat all chronic pain are not supported by the heterogeneous human evidence.

Current UK guidance cited here supports selected specialist laser or IPL modalities for persistent rosacea erythema/telangiectasia, but it does not recommend red/NIR PBM as routine primary-care anti-ageing treatment.

Similarly, NICE CKS notes little or no efficacy evidence for laser therapy in Morton’s neuroma, reinforcing that evidence from one indication cannot be extrapolated to another.

Related Knowledge Topics

Educational content only. Always verify information and use clinical judgement.

Continue exploring

Explore these topics in the iatroX reference and learning libraries.

UK clinical guidanceRosacea: primary care diagnosis and stepwise treatmentKnowledge CentreAcne VulgarisUKMLA AcademyRosaceaUK clinical guidanceAcne vulgarisUKMLA AcademyAcne Vulgaris